<p>Get up to date with the latest EHA-EU guideline for Mantle Cell Lymphoma (<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/hem3.70233" target="_blank" rel="noreferrer noopener"><u>EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library</u></a>) with Prof Mats Jerkeman (Lund University, Sweden).  </p><p><br></p><p>In this episode, he explains how biological risk factors, particularly <em>TP53 </em>mutations and proliferation rate, inform patient stratification. He reviews evolving treatment sequencing, including  the expanding role of  BTK inhibitors (such as ibrutinib) in first-line regimens. </p><p><br></p><p>He further discusses the management relapsed/refractory MCL, where BTK inhibitors and CAR T-cell therapy  have largely supplanted but not fully replaced allogeneic transplantation. </p><p>Throughout the conversation, Prof Jerkeman emphasizes the dynamic evolution of MCL treatment and the need for ongoing guideline updates as new evidence emerges. </p><p>  </p><p>Link to the guideline: (<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/hem3.70233" target="_blank" rel="noreferrer noopener"><u>EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma - Jerkeman - 2025 - HemaSphere - Wiley Online Library</u></a>) </p><p>Link to Lund University:  </p><p><a href="https://portal.research.lu.se/en/persons/mats-jerkeman/" target="_blank" rel="noreferrer noopener"><u>Mats Jerkeman - Lund University</u></a> </p><p><a href="https://www.lunduniversity.lu.se/" target="_blank" rel="noreferrer noopener"><u>Home | Lund University</u></a>  </p><p></p><p><strong>Learn More</strong></p><p><br></p><p>Interested in more content related to CART? We&#39;ve got you covered. Check out free CART program on <a href="https://ehacampus.ehaweb.org/ilp/pages/description.jsf?menuId=1106&client=#/users/@self/catalogues/1700/programmes/303993/description">⁠EHA Campus⁠</a>.</p><p><br></p><p>What did you think of this podcast? Share your opinions with us in this short feedback survey.</p><p><a href="https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1">⁠Provide Feedback⁠</a></p><p><br></p><p>Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.</p><p><a href="https://ehacampus.ehaweb.org/">⁠https://ehaedu.org/Campus⁠</a></p><p><br></p><p>Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.</p><p>Follow EHA on Instagram: <a href="https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged">⁠https://www.instagram.com/EHA_Hematology/⁠</a></p><p>Facebook: <a href="https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged">⁠https://e-h-a.link/facebook⁠</a></p><p>LinkedIn: <a href="https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged">⁠https://www.linkedin.com/company/eha/⁠</a></p><p>Email us: [email protected]</p><p>Subscribe to receive the EHA Educational Updates via <a href="https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged">⁠https://eha.news/subscribe⁠</a> </p>